Working… Menu

Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02135614
Recruitment Status : Completed
First Posted : May 12, 2014
Results First Posted : May 11, 2018
Last Update Posted : September 24, 2018
Information provided by (Responsible Party):
Gilead Sciences

Brief Summary:

The primary objective of this study is to evaluate the effects of presatovir on respiratory syncytial virus (RSV) viral load in RSV-positive adults who have been hospitalized with acute respiratory infectious symptoms.

Participants will receive 1 dose of presatovir on Day 1 and followed for 27 days postdose. Nasal swabs will be collected at each study visit (excluding Day 28) and assayed for change in viral load as the primary endpoint.

Condition or disease Intervention/treatment Phase
Respiratory Syncytial Virus Infection Drug: Presatovir Drug: Presatovir placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 189 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection
Actual Study Start Date : June 9, 2014
Actual Primary Completion Date : March 27, 2017
Actual Study Completion Date : April 12, 2017

Arm Intervention/treatment
Experimental: Presatovir
Participants will receive a single dose of presatovir.
Drug: Presatovir
Presatovir 200 mg (4 x 50 mg tablets) administered orally
Other Name: GS-5806

Placebo Comparator: Presatovir placebo
Participants will receive a single dose of presatovir placebo.
Drug: Presatovir placebo
Presatovir placebo tablets administered orally

Primary Outcome Measures :
  1. Time-Weighted Average Change in Respiratory Syncytial Viral (RSV) Load From Baseline to Day 5 [ Time Frame: Baseline to Day 5 ]
    The time-weighted average change, often referred to as the DAVG, provides the average viral burden change from baseline. The mean values presented were calculated using the ANCOVA model and are adjusted for baseline value and stratification factor.

Secondary Outcome Measures :
  1. Time-weighted Average Change in the Flu-PRO Score From Baseline to Day 5 [ Time Frame: Baseline to Day 5 ]
    The Flu-PRO is a patient-reported outcome questionnaire utilized as a standardized method for evaluating symptoms of influenza. Flu-PRO Score was calculated as the mean of 38 individual scores. Individual scores ranged from 0 (no symptoms) to 4 (worst symptoms). The mean values presented were calculated using the ANCOVA model and are adjusted for baseline value and stratification factor.

  2. Number of Hospitalization-Free Days Following Presatovir Administration [ Time Frame: Up to Day 28 ]
  3. Rate of Unplanned Medical Encounters [ Time Frame: Up to Day 28 ]
    The adjusted rate of unplanned medical encounters (clinic visits, emergency room visits, urgent care visits, and rehospitalizations) related to a respiratory illness after initial hospital discharge through Day 28 will be assessed. Event rate was calculated as the total number of unplanned medical encounters divided by the total number of participants. The mean values presented were adjusted for stratification factor.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Current inpatient
  • New onset of acute respiratory infectious symptoms, or acute worsening of chronic symptoms related to ongoing respiratory disease for ≤ 5 days prior to screening:

    • Upper respiratory tract symptoms: nasal congestion, runny nose, sore throat, or earache
    • Lower respiratory tract symptoms: cough, sputum production, wheezing, dyspnea, or chest tightness
  • Documented to be RSV-positive at the current admission within 72 hours of screening, or as evaluated at screening

Key Exclusion Criteria:

  • Related to concomitant or previous medication use:

    • Use of oral prednisone or other corticosteroid equivalent to:

      • > 20 mg/day for > 14 days prior to screening is not permitted.
      • > 20 mg/day for ≤ 14 days, including corticosteroids received during current hospitalization (ie, bolus doses), is permitted.
      • ≤ 20 mg/day, regardless of duration, is permitted.
    • Individuals taking a moderate or strong cytochrome P450 enzyme (CYP) inducer including but not limited to rifampin, St John's Wort, carbamazepine, phenytoin, efavirenz, bosentan, etracirine, modafinil, and nafcillin within 2 weeks prior to the first dose of study drug
  • Related to medical history:

    • Pregnant, breastfeeding, or lactating females
    • Individuals requiring > 50% supplemental oxygen (while the individual is awake) at screening
    • Individuals with a Clinical Frailty Scale (CFS) > 7 at Baseline
    • Known significant abnormality altering the anatomy of the nose or nasopharynx that in, the opinion of the investigator, will preclude obtaining adequate nasal swab sampling in either nasal passage
    • Waiting for or recently (within the past 12 months) received a bone marrow, stem cell, or solid organ transplant, or who have received radiation or chemotherapy within 12 months prior to Screening
    • Individuals with HIV/AIDS and a known CD4 count < 200 cells/uL
    • History of severe dementia or Alzheimer's disease
    • History of drug and/or alcohol abuse that, in the opinion of the investigator, may prevent adherence to study activities
  • Related to medical condition at screening:

    • Influenza-positive as determined by local diagnostic test
    • Known Middle East Respiratory Syndrome coronavirus (MERS-CoV) infection or known coinfection with other coronavirus
    • Use of mechanical ventilation during the current admission, not including noninvasive ventilation
    • Clinically significant bacteremia or fungemia that has not been adequately treated prior to Screening, as determined by the investigator
    • Inadequate treatment of confirmed bacterial, fungal, or non-RSV pneumonia, as determined by the investigator
    • Excessive nausea/vomiting at admission, as determined by the investigator, that precludes administration of an orally administered study drug
  • Related to allergies:

    • Known allergy to components of the study drug (microcrystalline cellulose, mannitol, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol and talc)
    • Documented history of acute (anaphylaxis) or delayed (Stevens-Johnson syndrome or epidermal necrolysis) allergy to sulfa drugs

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02135614

Show Show 43 study locations
Sponsors and Collaborators
Gilead Sciences
Layout table for investigator information
Study Director: Gilead Study Director Gilead Sciences
  Study Documents (Full-Text)

Documents provided by Gilead Sciences:
Study Protocol: Original  [PDF] November 10, 2013
Study Protocol: Amendment 1  [PDF] March 13, 2014
Study Protocol: Amendment 2  [PDF] August 5, 2014
Study Protocol: Amendment 3  [PDF] August 29, 2014
Study Protocol: Amendment 4  [PDF] November 17, 2015
Statistical Analysis Plan  [PDF] August 17, 2017

Layout table for additonal information
Responsible Party: Gilead Sciences Identifier: NCT02135614    
Other Study ID Numbers: GS-US-218-1227
2014-002137-58 ( EudraCT Number )
First Posted: May 12, 2014    Key Record Dates
Results First Posted: May 11, 2018
Last Update Posted: September 24, 2018
Last Verified: May 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Respiratory Syncytial Virus Infections
Virus Diseases
Pneumovirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections